Centiva Capital LP Buys Shares of 5,087 Masimo Co. (NASDAQ:MASI)

Centiva Capital LP bought a new position in shares of Masimo Co. (NASDAQ:MASI - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,087 shares of the medical equipment provider's stock, valued at approximately $678,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. NBC Securities Inc. raised its holdings in Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider's stock worth $30,000 after purchasing an additional 73 shares in the last quarter. GAMMA Investing LLC raised its stake in Masimo by 75.0% during the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider's stock worth $33,000 after acquiring an additional 111 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider's stock valued at $44,000 after acquiring an additional 200 shares during the last quarter. HHM Wealth Advisors LLC boosted its stake in Masimo by 25.0% in the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider's stock valued at $79,000 after acquiring an additional 125 shares in the last quarter. Finally, Fifth Third Bancorp grew its holdings in shares of Masimo by 16.4% during the second quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider's stock worth $88,000 after purchasing an additional 98 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on MASI shares. Wells Fargo & Company boosted their target price on Masimo from $160.00 to $171.00 and gave the company an "overweight" rating in a report on Wednesday, November 6th. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research note on Wednesday, November 6th. BTIG Research raised their target price on shares of Masimo from $166.00 to $170.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Stifel Nicolaus reaffirmed a "buy" rating and issued a $190.00 target price (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Finally, Piper Sandler increased their price target on shares of Masimo from $165.00 to $180.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $167.00.

Masimo Stock Performance

NASDAQ:MASI traded up $0.40 during midday trading on Friday, reaching $169.79. The stock had a trading volume of 253,379 shares, compared to its average volume of 513,913. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The stock has a market cap of $9.09 billion, a P/E ratio of 117.10 and a beta of 1.01. The firm has a fifty day simple moving average of $153.35 and a two-hundred day simple moving average of $131.52. Masimo Co. has a 12-month low of $101.35 and a 12-month high of $178.27.

Masimo (NASDAQ:MASI - Get Free Report) last released its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping the consensus estimate of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $504.60 million during the quarter, compared to analysts' expectations of $502.87 million. The business's revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the business earned $0.63 EPS. On average, equities analysts expect that Masimo Co. will post 4.03 EPS for the current year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.